Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

This study tests a new two-drug combination (tecotabart vedotin plus tislelizumab) against the standard treatment (tislelizumab plus chemotherapy) for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the new …

This study is testing a new injection called TQB2825 against standard immunotherapy for people with follicular lymphoma that has returned or hasn't responded to previous treatments. The main goal is to see which treatment keeps the cancer from getting worse for a longer time. Res…